Abstract
Background: Osteopenia and osteoporosis are highly prevalent and often undertreated conditions in postmenopausal women, partly due to concerns about adverse effects and cost of pharmacologic therapies. Bone-Viva is a multi-ingredient nutraceutical formulation designed to support bone metabolism through nutritional and biochemical pathways.
Objective: To determine whether Bone-Viva stabilizes or improves bone mineral density (BMD) in women with osteopenia or osteoporosis and to evaluate its comparative and additive effects relative to denosumab, romosozumab, and combination therapy (Bone-Viva plus either denosumab or romosozumab).
Methods: This retrospective observational analysis included 51 women aged 54"“90 years with osteopenia or osteoporosis. Patients received Bone-Viva monotherapy (n=12), denosumab (n=13), romosozumab (n=13), or Bone-Viva combined with either agent (n=13). Baseline and 1-year DEXA scans (Hologic Horizon W) assessed T-scores at the lumbar spine, femoral neck, and total hip. T-score changes were categorized as improved, stable, or declined using a ±0.1 threshold. Adverse events were recorded.
Results: The largest lumbar spine improvements of occurred with combination therapy T-score of (+0.20) and denosumab T-score of (+0.18), with 60"“65% of patients improving. romosozumab produced a T-score +0.12 increase (48% improved), and Bone-Viva monotherapy showed a t-score +0.18 increase (42% improved). Femoral neck changes were modest for all groups. All groups showed excellent stability of (60%) in the femoral neck. At the total hip, all groups demonstrated small but consistent gains, led by combination therapy (+0.17). Bone-Viva stabilized T-scores in 45"“48% of patients. One minor adverse event (transient stomach discomfort) was reported.
Conclusion: Bone-Viva was well tolerated and appeared to stabilize or modestly improve T-scores, particularly in patients with early bone loss. Combination therapy yielded the greatest overall improvements, suggesting potential synergistic benefit. Bone-Viva may offer a safe, economical adjunct or alternative for individuals seeking non-pharmacologic approaches to maintaining bone health. Larger prospective studies are warranted to validate these findings.